On Monday, Champions Oncology (NASDAQ:CSBR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Champions Oncology (NASDAQ:CSBR) released third-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
On Thursday, Champions Oncology (NASDAQ:CSBR) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Champions Oncology Inc (CSBR) posted 9% revenue growth, 50% gross margin, and record data licensing revenue in Q1 fiscal 2027.
Detailed price information for Champions Oncolog (CSBR-Q) from The Globe and Mail including charting and trades.
Motley Fool Press Release.
Moby summary of Champions Oncology, Inc.'s Q1 2027 earnings call
Champions Oncology (NASDAQ:CSBR) reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results. Revenue for the quarter totaled $15.2
Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026.First Quarter and Recent Highlights: * Revenue of $15.
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.
New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.-based workflowHACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / , a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.
This is the newest page. Registered accounts read further back.